Requip (ropinirole hydrochloride), an orally administered anti-Parkinsonian drug, is a non-ergoline dopamine agonist.
Requip (ropinirole hydrochloride) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Media Articles Related to Requip (Ropinirole)
Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2014.07.14]
Up to 70% of Parkinson's disease (PD) patients experience sleep problems that negatively impact their quality of life.
Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.07.09]
Biotie announces that full data from the positive Phase 2b study evaluating tozadenant, an adenosine A2a antagonist, in Parkinson's disease patients experiencing end of dose wearing off have been...
Source: MedicineNet amantadine Specialty [2013.12.04]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/4/2013 12:00:00 AM
Parkinson's Disease Quiz: Test Your Medical IQ
Source: MedicineNet amantadine Specialty [2011.08.31]
Title: Parkinson's Disease Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 8/23/2011 12:53:00 PM
Last Editorial Review: 8/31/2011 2:27:29 PM
Human neurodegenerative diseases may be impacted by discovery of a new cellular garbage control pathway
Source: Huntingtons Disease News From Medical News Today [2014.07.22]
Several human neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and Huntington's disease but also ageing, are linked to an accumulation of abnormal and aggregated...
Published Studies Related to Requip (Ropinirole)
PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. [2011.06]
BACKGROUND: PREPARED was a randomized, parallel-group, double-blind, multicenter study to evaluate the efficacy of adjunctive ropinirole prolonged release (PR) versus immediate release (IR) in patients with advanced Parkinson's disease (PD)... CONCLUSIONS: Adjunctive PR provided a significantly greater improvement in symptom control in terms of the odds of achieving >/= 20% maintained reduction in time spent "off" compared with IR. Interpretation may be confounded by the higher doses of PR versus IR that were achieved, in combination with lower doses of L-dopa by the study end. Despite dosing differences, the PR titration regimen was generally well tolerated, with an AE profile similar to that of IR. Copyright (c) 2011 Movement Disorder Society.
Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. [2011.06]
Comorbid depressive symptoms in restless legs syndrome (RLS) remain a treatment challenge, as some antidepressants aggravate RLS symptoms...
Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. [2011.04]
BACKGROUND: Pramipexole and ropinirole have become the first-line treatment for restless legs syndrome. The aim of this study was to perform the first direct comparison between these two molecules in restless legs syndrome... No significant side effects, except for mild morning nausea (2 patients treated with ropinirole, 3 with pramipexole, and 1 with placebo), were reported.
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. [2010.05.15]
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa...
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. [2010.05.15]
Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104)...
Clinical Trials Related to Requip (Ropinirole)
A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's [Completed]
This study was designed to compare the effectiveness and tolerability of a new prolonged
release formulation of ropinirole with the currently marketed immediate release formulation
which is prescribed in many countries. The new prolonged release formulation allows the drug
to be taken once a day rather than three times a day. This study will also evaluate the side
effects of the new prolonged release formulation of ropinirole
Study to Observe the Effect of Requip PDŽ Once-daily (QD) Versus Twice-daily (BID) [Recruiting]
1. In order to observe the benefit, side effects, and patient preference of Requip PD when
used in QD or BID dosing
2. In order to estimate the conversion rate of dopamine agonists into Requip PD
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) [Completed]
Treating Sexual Dysfunction From SSRI Medication: a Study Comparing Requip CR to Placebo [Active, not recruiting]
Antidepressant medicines sometimes cause sexual side effects. The purpose of this study is to
determine whether the sexual dysfunction sometimes caused by selective serotonin reuptake
inhibitor (SSRI) antidepressant medications can be reversed by treatment with Requip
(ropinirole), a medicine which is used to treat Parkinson's Disease and restless leg
Long-Term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164 [Active, not recruiting]
The purpose of this study is to obtain information on the long-term safety, tolerability, and
therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for
patients who participated in either Study 167 or Study 164 to continue receiving ropinirole
XL if they chose to do so.
Reports of Suspected Requip (Ropinirole) Side Effects
Drug Ineffective (46),
Pathological Gambling (30),
Sudden Onset of Sleep (27),
Confusional State (25),
Fall (16), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 10 ratings/reviews, Requip has an overall score of 8.20. The effectiveness score is 8.80 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Requip review by 53 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || Restless leg syndrome|
|Dosage & duration:|| || 0.5 mg taken at bedtime for the period of 2 years|
|Other conditions:|| || Sleeplessness|
|Other drugs taken:|| || None|
|Benefits:|| || While standing, my legs were fine, but aching, cramping legs were keeping me from getting any sleep. My doctor suggested I try Requip, and its been the best thing I have done.|
|Side effects:|| || I have experienced no side effects, except sleeping at night. The warning says that it might make you drowsy, but that's also why they say to take it at night.|
|Comments:|| || I take Requip about 1-1/2 to 2 hours before bedtime. It permits relaxation of legs so I can sleep.|
Requip review by 40 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || RLS|
|Dosage & duration:|| || 1 mg/day taken 1 for the period of 1 yr|
|Other conditions:|| || none|
|Other drugs taken:|| || birth control|
|Benefits:|| || my legs stay still so i can get to sleep and stay asleep|
|Side effects:|| || i feel nauseated about 1/2 hour after i take it|
|Comments:|| || I take 1 -1.5 mg per night about an hour before i go to bed. it stops the feeling of havingto move my legs and quiets them while i sleep so i can get sustained deep sleep.|
Requip review by 63 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Marginally Effective|
|Side effects:|| || Extremely Severe Side Effects|
|Condition / reason:|| || RLS associated with sleep apnea|
|Dosage & duration:|| || 3mg taken nightly for the period of 3 months|
|Other conditions:|| || diabetes|
|Other drugs taken:|| || Novalog|
|Benefits:|| || None|
|Side effects:|| || Began with Requip pack and gradually increased dosage. Immediately felt more lethargic and irritable. On my third week at 3mg. I could not keep any food down in the mornings. My doctor said the sleepiness and irritability was not related to Requip. After 10 days of vomiting in the a.m I stopped the medication. Feel much better even though my doctor insists I need it.
|Comments:|| || Gradually increased dosage. After last overnight sleep study doctor increased by dosage to 3 mg. That's when the severe nausea and then followed by vomiting.|
Page last updated: 2014-07-22